Dr Seto (National Kyushu Cancer Center, Kyushu, Japan) and Dr Yoh (National Cancer Center Hospital East, Kashiwa, Japan) talk to ecancertv at ASCO 2016 about RET fusions, known oncogenes from a small subset of non-small cell lung cancer (NSCLC).
Out of 196 institutions in Japan (LC-SCRUM-Japan), 17 RET-rearranged patients who had previously failed to respond to chemotherapy were given vandetanib, a TKI with RET kinase activity.
Dr Seto and Dr Yoh report that vandetanib increased anti-tumour activity, progression free survival and and partial response rates, especially among those from the CCDC6-RET subtype.
ecancer's filming at ASCO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.